Pasithea Therapeutics Corp (KTTA) Stock Analysis
Verdict: WATCH (do not buy)
Net-cash valuation discount provides downside cushion for PAS-004 clinical catalysts, but massive authorized share expansion limits upside.
Investment score: 46/100
Analysis as of
Is Pasithea Therapeutics Corp stock worth reviewing? The TradeMates thesis
TradeMates rates KTTA as WATCH: a negative Enterprise Value biotech backed by ~28 months of cash runway, offset by complete pre-revenue risk and severe dilution capacity.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 42/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Pasithea Therapeutics Corp opportunities and risks
What speaks for KTTA
- Clinical Data Readout Catalysts for PAS-004
What speaks against KTTA
- Severe Dilution Risk from 500M Share Expansion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KTTA | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -100.4% |
| MCRB | n/a | 10.3x | n/a | 29.5% | -1192.9% | -263.3% |
| ESLA | n/a | 0.0x | n/a | 0.0% | 0.0% | -51.6% |
| ACUT | n/a | 23.3x | n/a | 100.0% | -1680.0% | -52.4% |
| ALLR | n/a | 52.1x | n/a | 107.5% | -3575.1% | -76.7% |
| KYNB | 0.1x | 3.8x | 0.4x | 18.2% | 3967.8% | -218.1% |
| Peer median | n/a | 10.3x | n/a | 29.5% | -1192.9% | -76.7% |
Frequently asked questions about Pasithea Therapeutics Corp (KTTA)
Is KTTA stock a good investment?
The TradeMates model rates Pasithea Therapeutics Corp as WATCH (do not buy) with an investment score of 46/100. TradeMates rates KTTA as WATCH: a negative Enterprise Value biotech backed by ~28 months of cash runway, offset by complete pre-revenue risk and severe dilution capacity. This is algorithmic model output, not personal investment advice.
Is KTTA stock a buy?
The TradeMates model verdict for KTTA is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.